RT @RichardPAConway: Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4%
Tweet Content
Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c
Links
EULAR Abstract Archive
http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=OP0255&view=1&item=2…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off